GO
Loading...

Enter multiple symbols separated by commas

Sanofi SA

More

  • *Sacked former CEO's 4.44 million euros exit deal approved. *Brandicourt also gets extra 4 million euros golden hello. Investor advisory group ISS had recommended a vote against both resolutions, prompting the Sanofi board to appeal for loyalty and call ISS's advice "a real error in analysis."

  • *Sanofi says opposition to both deals a "real error". PARIS, April 30- Drugs group Sanofi, which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men. In exchange, he agreed not to work for a competitor until June, not to...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • PARIS, April 30- France's Sanofi warned revenue in its key diabetes division would fall this year after it was forced to offer discounts for its best-selling drug Lantus in the United States. Global sales of Lantus, which accounts for almost a fifth of the company's revenue but is due to go off-patent in the United States this year, fell 5 percent at constant...

  • Sanofi keeps 2015 guidance with steady Q1 profits Thursday, 30 Apr 2015 | 1:42 AM ET

    PARIS, April 30- Drugs firm Sanofi maintained its guidance for stable to slightly growing 2015 profit on Thursday as first-quarter earnings grew modestly and beat expectations despite declining sales of its main drug Lantus. But this impact was offset by strong operating profit growth in its Genzyme, Generics, Consumer Healthcare and Animal Health...

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • April 7- Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial. Tresiba, already available outside the United States, was rebuffed by the FDA two years ago on concerns that the drug could be linked to higher rates of heart...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...

  • *Novo to submit interim trial data for Tresiba with FDA. The drug was rebuffed by the FDA two years ago. Citigroup's Peter Verdult said he believed the odds of U.S. approval were greater than 90 percent, given a small group of Novo staff sitting behind a communications "firewall" had already discussed the data with FDA.

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Cramer: Snap up this incredible opportunity Thursday, 19 Mar 2015 | 6:22 PM ET
    Lab technician handling test tubes

    Jim Cramer can't believe how Esperion Therapeutics stock has shot through the roof! Can it keep going?

  • PARIS, March 19- Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday. Sanofi was reporting the results of a study it has been waiting to complete before seeking U.S. approval. At the time Sanofi said it would re-submit a U.S. new drug application with...

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...